Effects of cetirizine on substance P release in patients with perennial allergic rhinitis.
To evaluate the effect of cetirizine hydrochloride on substance P release in allergic rhinitis, we performed a single-blind placebo-controlled study of 14 patients with perennial allergic rhinitis (7 treated with cetirizine and 7 with placebo). After an initial nasal allergen challenge with lavages, the subjects received treatment with placebo or cetirizine hydrochloride (10 mg by mouth daily) for 1 week, followed by the second nasal allergen challenge with lavages. The levels of albumin, histamine, and substance P in nasal lavages before and after allergen challenge were quantified by enzyme-linked immunosorbent assay. Pretreatment of subjects with cetirizine reduced the level of substance P induced by antigen challenge, but did not significantly reduce levels of histamine. These results suggest that cetirizine may reduce nasal neurogenic inflammation by modulating the release of substance P in allergic rhinitis.
Shirasaki
Hideaki
H
Department of Otolaryngology, Sapporo Medical University, School of Medicine, Sapporo, Japan.
Watanabe
Kazumasa
K
Kanaizumi
Etsuko
E
Sato
Jun
J
Konno
Nobuhiro
N
Narita
Shin-ichirou
S
Himi
Tetsuo
T
D000328:Adult; D000403:Airway Resistance; D000418:Albumins / Q000032:analysis; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D017332:Cetirizine / Q000627:therapeutic use*; D005260:Female; D006632:Histamine / Q000032:analysis; D039563:Histamine H1 Antagonists, Non-Sedating / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017817:Nasal Lavage Fluid / Q000737:chemistry; D009299:Nasal Provocation Tests; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D016037:Single-Blind Method; D013373:Substance P / Q000378:metabolism*
D000418:Albumins; D018926:Anti-Allergic Agents; D039563:Histamine H1 Antagonists, Non-Sedating; D013373:Substance P; D006632:Histamine; D017332:Cetirizine